{"filing":{"accession_number":"0001776985-26-000059","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"form6-kxfgvariantvaccinefd.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/form6-kxfgvariantvaccinefd.htm"},"events":[{"id":30104,"run_id":27588,"accession_number":"0001776985-26-000059","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces FDA approval of a supplemental Biologics License Application (sBLA) for an updated COVID-19 vaccine formula (COMIRNATY XFG) targeting the XFG variant for the 2026-2027 season. The approval is a regulatory milestone for an existing product line rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter. While the approval enables commercial distribution and is material to investors assessing BioNTech's vaccine business prospects, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment). This is best classified as an operational/strategic milestone—a material product approval and launch announcement.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":[{"id":32607,"accession_number":"0001776985-26-000059","item_number":"EX-99.1","item_title":"a991bntx_covid-19xfgvarian.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces FDA approval of a supplemental Biologics License Application (sBLA) for an updated COVID-19 vaccine formula (COMIRNATY XFG) targeting the XFG variant for the 2026-2027 season. The approval is a regulatory milestone for an existing product line rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter. While the approval enables commercial distribution and is material to investors assessing BioNTech's vaccine business prospects, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment). This is best classified as an operational/strategic milestone—a material product approval and launch announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:55:45.617075+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32607,"accession_number":"0001776985-26-000059","item_number":"EX-99.1","item_title":"a991bntx_covid-19xfgvarian.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces FDA approval of a supplemental Biologics License Application (sBLA) for an updated COVID-19 vaccine formula (COMIRNATY XFG) targeting the XFG variant for the 2026-2027 season. The approval is a regulatory milestone for an existing product line rather than a discrete financial event (earnings, debt, M\u0026A) or governance matter. While the approval enables commercial distribution and is material to investors assessing BioNTech's vaccine business prospects, it does not fit the specific event types (e.g., earnings_release, ma_activity, exec_appointment). This is best classified as an operational/strategic milestone—a material product approval and launch announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:55:45.617075+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-27"}]}